According to the research report titled, ‘Europe Haematococcus Pluvialis Market by Product (Astaxanthin Ingredients {Oleoresin, Beadlets}), Astaxanthin Bulk Finished Products {Capsules, Tablets}), Application (Nutraceuticals, Aquaculture, Cosmetics, Food), and Geography - Forecast to 2030,’ in terms of value, the Europe Haematococcus pluvialis market is projected to reach $35.0 million by 2030, at a CAGR of 13.4% from 2023 to 2030, while in terms of volume, this market is projected to reach 241.44 tons by 2030, at a CAGR of 14.5% from 2023 to 2030. The report provides an in-depth analysis of the Haematococcus pluvialis market across Europe, current market trends, size, recent developments, and the forecast till 2030.
Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges.
The growth of this market is driven by increasing demand for natural astaxanthin for nutraceuticals, growing demand for natural food colorants, and increasing awareness of clean-label products. However, the high production cost is expected to restrain the growth of this market.
The rising demand for natural astaxanthin and the growing use of natural astaxanthin in poultry and aquaculture is expected to create market growth opportunities. However, the complex production process for Haematococcus pluvialis is a major challenge for the players operating in this market. Additionally, the increasing need for natural self-grooming products is a prominent trend in the Europe Haematococcus pluvialis market.
Based on product, the Europe Haematococcus pluvialis market is mainly segmented into astaxanthin ingredients and astaxanthin bulk finished products. In 2023, the astaxanthin ingredients segment is expected to account for the largest share of the Europe Haematococcus pluvialis market. The large share of this segment is mainly attributed to the growing end-use applications of astaxanthin ingredients, rising awareness about preventive healthcare & nutraceuticals, rising demand for natural antioxidants, growing cosmetic & personal care markets, and government initiatives to support the aquaculture industry.
Based on application, the Europe Haematococcus pluvialis market is segmented into nutraceuticals, aquaculture and animal feed, cosmetics, food and beverages, and pharmaceuticals. In 2023, the nutraceuticals segment is expected to account for the largest share of the Europe Haematococcus pluvialis market. The large market share of this segment is primarily attributed to the increasing demand for natural astaxanthin derived from haematococcus in the nutraceuticals industry. This demand is driven by the potential health benefits that astaxanthin may provide, including its effects on various diseases such as cancers, hypertension, diabetes, cardiovascular and gastrointestinal disorders, neurodegenerative diseases, and certain skin conditions.
An in-depth geographic analysis of the market provides detailed qualitative and quantitative insights into the ten major countries/regions in Europe (Germany, the U.K., Italy, France, Sweden, Spain, Russia, Netherlands, Denmark, Poland, and the Rest of Europe). The U.K. is expected to witness significant growth during the forecast period, mainly due to the rapidly growing vegan population, people’s drive towards maintaining a healthy dietary regime, and the well-established F&B industry.
The key players operating in the Europe Haematococcus pluvialis market are E.I.D. - Parry (India) Limited (A Subsidiary of M/S. Ambadi Investments Limited) (India), Cyanotech Corporation (U.S.), YUNNAN GREEN A BIOLOGICAL PROJECT CO., LTD. (Yunnan Spirin Biotechnology Co. Ltd) (China), Sun Chlorella Corporation (Japan), Roquette Klötze GmbH & Co. KG (Germany), Tianjin Norland Biotech Co., Ltd (China), Aliga Microalgae (Denmark), DAESANG Corporation (Korea), BlueBioTech Group (Germany), Algatechnologies Ltd. (A Part of Solabia Group) (Israel), AstaReal Group (Japan), BEIJING GINGKO GROUP (BGG) (U.S.), FENCHEM (China), PIVEG, Inc. (U.S.), Algamo s.r.o. (Czech Republic), Algalíf Iceland ehf. (Part of Sana Pharma Industries) (Iceland), Atacama Bio Natural Products S.A. (Chile), BDI BioLife Science GmbH (Austria), Sea & Sun Organic GmbH (Subsidiary of Sea & Sun Technology GmbH) (Germany), Pond Technologies Inc. (Canada), Algicel, Biotecnologia e Investigação, Lda (Portugal), and Astaxa GmbH (Germany).
Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges.
The growth of this market is driven by increasing demand for natural astaxanthin for nutraceuticals, growing demand for natural food colorants, and increasing awareness of clean-label products. However, the high production cost is expected to restrain the growth of this market.
The rising demand for natural astaxanthin and the growing use of natural astaxanthin in poultry and aquaculture is expected to create market growth opportunities. However, the complex production process for Haematococcus pluvialis is a major challenge for the players operating in this market. Additionally, the increasing need for natural self-grooming products is a prominent trend in the Europe Haematococcus pluvialis market.
Based on product, the Europe Haematococcus pluvialis market is mainly segmented into astaxanthin ingredients and astaxanthin bulk finished products. In 2023, the astaxanthin ingredients segment is expected to account for the largest share of the Europe Haematococcus pluvialis market. The large share of this segment is mainly attributed to the growing end-use applications of astaxanthin ingredients, rising awareness about preventive healthcare & nutraceuticals, rising demand for natural antioxidants, growing cosmetic & personal care markets, and government initiatives to support the aquaculture industry.
Based on application, the Europe Haematococcus pluvialis market is segmented into nutraceuticals, aquaculture and animal feed, cosmetics, food and beverages, and pharmaceuticals. In 2023, the nutraceuticals segment is expected to account for the largest share of the Europe Haematococcus pluvialis market. The large market share of this segment is primarily attributed to the increasing demand for natural astaxanthin derived from haematococcus in the nutraceuticals industry. This demand is driven by the potential health benefits that astaxanthin may provide, including its effects on various diseases such as cancers, hypertension, diabetes, cardiovascular and gastrointestinal disorders, neurodegenerative diseases, and certain skin conditions.
An in-depth geographic analysis of the market provides detailed qualitative and quantitative insights into the ten major countries/regions in Europe (Germany, the U.K., Italy, France, Sweden, Spain, Russia, Netherlands, Denmark, Poland, and the Rest of Europe). The U.K. is expected to witness significant growth during the forecast period, mainly due to the rapidly growing vegan population, people’s drive towards maintaining a healthy dietary regime, and the well-established F&B industry.
The key players operating in the Europe Haematococcus pluvialis market are E.I.D. - Parry (India) Limited (A Subsidiary of M/S. Ambadi Investments Limited) (India), Cyanotech Corporation (U.S.), YUNNAN GREEN A BIOLOGICAL PROJECT CO., LTD. (Yunnan Spirin Biotechnology Co. Ltd) (China), Sun Chlorella Corporation (Japan), Roquette Klötze GmbH & Co. KG (Germany), Tianjin Norland Biotech Co., Ltd (China), Aliga Microalgae (Denmark), DAESANG Corporation (Korea), BlueBioTech Group (Germany), Algatechnologies Ltd. (A Part of Solabia Group) (Israel), AstaReal Group (Japan), BEIJING GINGKO GROUP (BGG) (U.S.), FENCHEM (China), PIVEG, Inc. (U.S.), Algamo s.r.o. (Czech Republic), Algalíf Iceland ehf. (Part of Sana Pharma Industries) (Iceland), Atacama Bio Natural Products S.A. (Chile), BDI BioLife Science GmbH (Austria), Sea & Sun Organic GmbH (Subsidiary of Sea & Sun Technology GmbH) (Germany), Pond Technologies Inc. (Canada), Algicel, Biotecnologia e Investigação, Lda (Portugal), and Astaxa GmbH (Germany).
Key Questions Answered in the Report:
- What is the revenue generated by the Europe Haematococcus pluvialis market?
- At what rate is the Europe demand for Haematococcus pluvialis projected to grow for the next 5-7 years?
- What is the historical market size and growth rate for the Europe Haematococcus pluvialis market?
- What are the major factors impacting the growth of this market?
- What are the major opportunities for existing players and new entrants in the market?
- Which product and application segments create major traction for the manufacturers in this market?
- What are the key country-level trends in this market? Which countries are expected to offer significant growth opportunities for the manufacturers operating in the Europe Haematococcus pluvialis market?
- Who are the major players in the Europe Haematococcus pluvialis market? What are their specific product offerings in this market?
- What recent developments have taken place in the Europe Haematococcus pluvialis market? What are the impacts of these strategic developments on the market?
Scope of the Report:
Europe Haematococcus Pluvialis Market - by Product
- Astaxanthin Ingredients
- Astaxanthin Oleoresin
- Beadlets
- Whole Biomass Powder
- Water Dispersible Powder
- Astaxanthin Bulk Finished Products
- Capsules/Softgels
- Tablets
Europe Haematococcus Pluvialis Market - by Application
- Nutraceuticals
- Aquaculture and Animal Feed
- Cosmetics
- Food & Beverages
- Pharmaceuticals
Europe Haematococcus Pluvialis Market - by Geography
- Germany
- U.K.
- Italy
- France
- Sweden
- Spain
- Russia
- Netherlands
- Denmark
- Poland
- Rest of Europe (RoE)
Table of Contents
1. Market Definition & Scope
2. Research Methodology
3. Executive Summary
4. Market Insights
5. Europe Haematococcus Pluvialis Market Assessment - by Product
6. Europe Haematococcus Pluvialis Market Assessment - by Application
7. Europe Haematococcus Pluvialis Market Assessment - by Country/Region
8. Competition Analysis
9. Company Profiles
10. Appendix
List of Tables
List of Figures
Companies Mentioned
- E.I.D. - Parry (India) Limited (A Subsidiary of M/S. Ambadi Investments Limited) (India)
- Cyanotech Corporation (U.S.)
- YUNNAN GREEN A BIOLOGICAL PROJECT CO. Ltd. (Yunnan Spirin Biotechnology Co. Ltd) (China)
- Sun Chlorella Corporation (Japan)
- Roquette Klötze GmbH & Co. KG (Germany)
- Tianjin Norland Biotech Co. Ltd (China)
- Aliga Microalgae (Denmark)
- DAESANG Corporation (Korea)
- BlueBioTech Group (Germany)
- Algatechnologies Ltd. (A Part of Solabia Group) (Israel)
- AstaReal Group (Japan)
- BEIJING GINGKO GROUP (BGG) (U.S.)
- FENCHEM (China)
- PIVEG Inc. (U.S.)
- Algamo s.r.o. (Czech Republic)
- Algalíf Iceland ehf. (Part of Sana Pharma Industries) (Iceland)
- Atacama Bio Natural Products S.A. (Chile)
- BDI BioLife Science GmbH (Austria)
- Sea & Sun Organic GmbH (Subsidiary of Sea & Sun Technology GmbH) (Germany)
- Pond Technologies Inc. (Canada)
- Algicel Biotecnologia e Investigação Lda (Portugal)
- Astaxa GmbH (Germany).
